Wegovy 7.2mg, the highest licensed Semaglutide dose, may help patients who've plateaued on 2.4mg
If you continue drawing the same number of units, your dose has suddenly halved or doubled
Maxler ,

Additional risk factors include: Type 2 diabetes with impaired counter-regulatory responses long-standing diabetes may blunt the body's natural protective mechanisms against hypoglycaemia Renal impairment reduced kidney function can affect drug clearance and alter glucose homeostasis, particularly if on insulin or sulphonylureas Hepatic dysfunction the liver plays a central role in glucose production and metabolism Excessive caloric restriction very low-calorie diets combined with Wegovy may precipitate symptoms mimicking hypoglycaemia Increased physical activity particularly unplanned or intense exercise without adequate carbohydrate intake Alcohol consumption alcohol inhibits hepatic glucose production and can mask hypoglycaemia symptoms Elderly patients may have reduced awareness of hypoglycaemic symptoms and altered drug metabolism According to the Wegovy SmPC, patients with type 1 diabetes should not use Wegovy , as it is not licensed for this indication and the complex insulin requirements make management challenging

Like all other factors, age can make a difference, but your age alone wont guarantee you do or dont find benefit from a nootropic supplement
Because GHK-Cu is a relatively large, hydrophilic molecule, formulation matters enormously